Pathfinder and SyntheMed announce merger

Pathfinder LLC and SyntheMed have announced that they have entered into a definitive merger agreement. Under the agreement SyntheMed will be renamed Pathfinder Cell Therapy Inc and the combined company will operate under the leadership of the Pathfinder management team. Pathfinder will be merged with and into a wholly-owned subsidiary of SyntheMed. Pathfinder shareholders will own around 80% and SyntheMed shareholders will own around 20% of the combined company.

About these ads